*European Journal of Pharmacology*, 135 (1987) 459–462
Elsevier



# AUTHOR INDEX TO VOLUME

Aalkjær, C., see Juul, B. (135) 61
Abe, T., see Koyano, K. (135) 337
Abel, P.W., see Fox, A.W. (135) 1
Adejare, A., see Fedyna, J.S. (135) 161
Adem, A., see Zhang, X. (135) 457
Agoston, S., see Biessels, P.T.M. (135) 155
Ahrén, B., see Alwmark, A. (135) 307
Akiba, T., see Toda, N. (135) 321
Alwmark, A. and Ahrén, B.
Phentolamine reverses NPY-induced inhibition of insulin secretion in isolated rat islets (135) 307
Amobi, N.I.B. and Smith, I.C.H.
Adrenergic and 'non-adrenergic' contributions to the two-component tetanus in the rat vas deferens (135) 173
Anderson, C.D., see Lindgren, B.R. (135) 383
Andersson, R.G.G., see Lindgren, B.R. (135) 383
Andrews, H.E., see Dashwood, M.R. (135) 111
Asami, T., see Naruse, T. (135) 365
Audi, E.A. and Graeff, F.G.
$GABA_A$ receptors in the midbrain central grey mediate the antiaversive action of GABA (135) 225
Awata, N., see Azuma, J. (135) 137
Azuma, J., Sawamura, A., Harada, H., Awata, N., Kishimoto, S. and Sperelakis, N.
Mechanism of direct cardiostimulating actions of hydralazine (135) 137

Badino, L., see Westfall, T.C. (135) 433
Barrio, V., De Arriba, G., López-Novoa, J.M. and Rodríguez-Puyol, D.
Atrial natriuretic peptide inhibits glomerular contraction induced by angiotensin II and platelet activating factor (135) 93
Barthó, L., Lembeck, F. and Holzer, P.
Calcitonin gene-related peptide is a potent relaxant of intestinal muscle (135) 449
Benveniste, J., see Davenas, E. (135) 313
Berendsen, H.H.G. and Broekkamp, C.L.E.
Drug-induced penile erections in rats: indications of $serotonin_{1B}$ receptor mediation (135) 279
Berti, F., Rossoni, G., Omini, C., Folco, G., Daffonchio, L., Viganó, T. and Tondo, C.
Defibrotide, an antithrombotic substance which prevents myocardial contracture in ischemic rabbit heart (135) 375
Bian, K., see Toda, N. (135) 321
Biessels, P.T.M., Houwertjes, M.C., Agoston, S. and Horn, A.S.
A comparison of the pharmacological actions of 4-aminopyridine and two of its derivatives in the monkey (135) 155
Biggio, G., see Concas, A. (135) 423
Blad, M.W.M., see Van Amsterdam, J.G.C. (135) 411
Böhme, E., see Mülsch, A. (135) 247
Boi, V., see Mereu, G. (135) 453
Braunwalder, A.F., see Loo, P.A. (135) 261
Broekkamp, C.L.E., see Berendsen, H.H.G. (135) 279
Brunello, N., see Rovescalli, A.C. (135) 129
Busse, R., see Mülsch, A. (135) 247

Calvo, D., see Novas, M.L. (135) 243
Canonico, P.L., see Sortino, M. (135) 77
Carcangiu, P., see Mereu, G. (135) 453
Casals-Stenzel, J.
Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock (135) 117
Champion, E., see Hall, R.A. (135) 193
Childers, S.R., see Nijssen, P.C.G. (135) 355
Concas, A., Mele, S. and Biggio, G.
Foot shock stress decreases chloride efflux from rat brain synaptoneurosomes (135) 423
Coulon, J.F., Lacroix, P., Linee, P. and David, J.C.
Effects of triethyltin on brain octopamines and their metabolism in the rat (135) 53
Couture, R., Gupta, A., Kérouac, R. and Regoli, D.
Studies on the cardiovascular effects produced by the spinal action of two substance P analogues in the rat: evidence for a central catecholaminergic mechanism (135) 345
Coyle, J.T., see Saltarelli, M.D. (135) 35
Cronin, M.J., see Sortino, M. (135) 77

Daffonchio, L., see Berti, F. (135) 375
Damsma, G., see Westerink, B.H.C. (135) 123
Dashwood, M.R., Andrews, H.E. and Wei, E.T.
Binding of [$^{125}$I]Tyr-corticotropin-releasing factor to rabbit aorta is reduced by removal of the endothelium (135) 111
Davenas, E., Poitevin, B. and Benveniste, J.
Effect on mouse peritoneal macrophages of orally administered very high dilutions of silica (135) 313
David, J.C., see Coulon, J.F. (135) 53
De Arriba, G., see Barrio, V. (135) 93
Depaulis, A., see Micheletti, G. (135) 397
De Robertis, E., see Novas, M.L. (135) 243
De Vries, J.B., see Westerink, B.H.C. (135) 123
Di Chiara, G., see Leone, P. (135) 251
Donoso, M.V., see Kullak, A. (135) 297
Dragunow, M., Peterson, M.R. and Robertson, H.A.
Presence of c-fos-like immunoreactivity in the adult rat brain (135) 113

0014-2999/87/$03.50 © 1987 Elsevier Science Publishers B.V.

Ethier, D., see Hall, R.A. (135) 193
Evans, J., see Hall, R.A. (135) 193

Fedyna, J.S., Adejare, A., Miller, D.D. and Feller, D.R.
Pharmacological evaluation of the β-adrenoceptor agonist and thromboxane antagonist properties of N-substituted trimetoquinol analogues (135) 161
Feller, D.R., see Fedyna, J.S. (135) 161
Ferreira, S.H., see Nakamura, M. (135) 145
Folco, G., see Berti, F. (135) 375
Ford-Hutchinson, A.W., see Hall, R.A. (135) 193
Fortin, R., see Hall, R.A. (135) 193
Fouque, F. and Vargaftig, B.B.
Potentiation and inhibition by clonidine of PAF-acether-induced human platelet activation (135) 211
Fox, A.W., Friedman, P.A. and Abel, P.W.
Vasopressin receptor mediated contraction and [$^3$H]inositol metabolism in rat tail artery (135) 1
Friedman, P.A., see Fox, A.W. (135) 1
Fukaya, H., see Nabeshima, T. (135) 23
Furukawa, H., see Nabeshima, T. (135) 23

Gessa, G.L., see Mereu, G. (135) 453
Gibb, J.W., see Johnson, M. (135) 231
Gillard, J., see Hall, R.A. (135) 193
Godfraind, T., see Morel, N. (135) 69
Graeff, F.G., see Audi, E.A. (135) 225
Guindon, Y., see Hall, R.A. (135) 193
Gupta, A., see Couture, R. (135) 345

Hall, R.A., Gillard, J., Guindon, Y., Letts, G., Champion, E., Ethier, D., Evans, J., Ford-Hutchinson, A.W., Fortin, R., Jones, T.R., Lord, A., Morton, H.E., Rokach, J. and Yoakim, C.
Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpropanoic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonist (135) 193
Handley, S.L., see Singh, L. (135) 419
Hanson, G.R., see Johnson, M. (135) 231
Harada, H., see Azuma, J. (135) 137
Hardy, J.-P., see Morel, N. (135) 69
Herz, A., see Schmauss, C. (135) 429
Heumann, R., see Van Calker, D. (135) 259
Hicks, P.E., see Medgett, I.C. (135) 443
Hieble, J.P., see Sulpizio, A. (135) 107
Hirata, Y., Hirose, S., Takata, S., Takagi, Y. and Matsubara, H.
Down-regulation of atrial natriuretic peptide receptor and cyclic GMP response in cultured rat vascular smooth muscle cells (135) 439
Hirose, S., see Hirata, Y. (135) 439
Hoang, N.D. and Sick, P.
Amplification of serotonin-induced contractions of isolated porcine coronary arteries after pretreatment with therapeutic doses of β-methyldigoxin (135) 89
Holzer, P., see Barthó, L. (135) 449
Horn, A.S., see Biessels, P.T.M. (135) 155
Hornykiewicz, O., see Pichler, L. (135) 239
Houwertjes, M.C., see Biessels, P.T.M. (135) 155
Huidobro-Toro, J.P., see Kullak, A. (135) 297
Huidobro-Toro, J.P., see Ureta, H. (135) 289

Ishii, K., Sasakawa, N. and Kato, R.
Simultaneous recording of tension and fluorescence ratio of the fura-2-loaded longitudinal muscle of guinea-pig ileum: responses to muscarinic agents (135) 455
Ishikawa, K., see Nabeshima, T. (135) 23

Johnson, M., Stone, D.M., Hanson, G.R. and Gibb, J.W.
Role of the dopaminergic nigrostriatal pathway in methamphetamine-induced depression of the neostriatal serotonergic system (135) 231
Johnson, N., Spinelli, W. and Rosen, M.R.
Cardiac electrophysiologic effects of R 54718 (135) 41
Jones, T.R., see Hall, R.A. (135) 193
Juul, B., Aalkjær, C. and Mulvany, M.J.
Responses of femoral resistance vessels to angiotensin in vitro (135) 61

Kagiya, T., see Mizushima, A. (135) 403
Kameyama, T., see Nabeshima, T. (135) 23
Kannisto, P., see Schmidt, G. (135) 11
Kato, R., see Ishii, K. (135) 455
Kérouac, R., see Couture, R. (135) 345
Kilbinger, H., see Wessler, I. (135) 85
Kishimoto, S., see Azuma, J. (135) 137
Kobinger, W., see Pichler, L. (135) 239
Koning, H., see Westerink, B.H.C. (135) 123
Kostowski, W., see Plaznik, A. (135) 389
Koyano, K., Abe, T., Nishiuchi, Y. and Sakakibara, S.
Effects of synthetic ω-conotoxin on synaptic transmission (135) 337
Kullak, A., Donoso, M.V. and Huidobro-Toro, J.P.
Extracellular calcium dependence of the neurotensin-induced relaxation of intestinal smooth muscles: studies with calcium channel blockers and BAY K-8644 (135) 297

Lacroix, P., see Coulon, J.F. (135) 53
Langer, S.Z., see Medgett, I.C. (135) 443
Lehoullier, P.F. and Ticku, M.K.
Benzodiazepine and β-carboline modulation of GABA-stimulated $^{36}$Cl-influx in cultured spinal cord neurons (135) 235
Lembeck, F., see Barthó, L. (135) 449
Leone, P. and Di Chiara, G.
Blockade of D-1 receptors by SCH 23390 antagonizes morphine- and amphetamine-induced place preference conditioning (135) 251
Letts, G., see Hall, R.A. (135) 193
Lindgren, B.R., Anderson, C.D. and Andersson, R.G.G.
Potentiation of inflammatory reactions in guinea-pig skin by an angiotensin converting enzyme inhibitor (MK 422) (135) 383

Linee, P., see Coulon, J.F. (135) 53
Loo, P.A., Braunwalder, A.F., Williams, M. and Sills, M.A.
The novel anticonvulsant MK-801 interacts with central phencyclidine recognition sites in rat brain (135) 261
López, L.F., see Ureta, H. (135) 289
López-Novoa, J.M., see Barrio, V. (135) 93
Lord, A., see Hall, R.A. (135) 193
Lowenstein, P.R., see Saltarelli, M.D. (135) 35

McWade, D., see Rangachari, P.K. (135) 331
Marescaux, C., see Micheletti, G. (135) 397
Martin, J.R. and Takemori, A.E.
Further evidence that a single dose of an opiate can increase dopamine receptor sensitivity in mice [1] (135) 203
Matsubara, H., see Hirata, Y. (135) 439
Medgett, I.C., Hicks, P.E. and Langer, S.Z.
Effect of acidosis on $\alpha_1$- and $\alpha_2$-adrenoceptor-mediated vasoconstrictor responses in isolated arteries (135) 443
Medina, J.H., see Novas, M.L. (135) 243
Meldrum, M.J., see Westfall, T.C. (135) 433
Mele, S., see Concas, A. (135) 423
Mereu, G., Passino, N., Carcangiu, P., Boi, V. and Gessa, G.L.
Electrophysiological evidence that Ro 15-4513 is a benzodiazepine receptor inverse agonist (135) 453
Micheletti, G., Warter , J.-M., Marescaux, C., Depaulis, A., Tranchant, C., Rumbach, L. and Vergnes, M.
Effects of drugs affecting noradrenergic neurotransmission in rats with spontaneous petit mal-like seizures (135) 397
Miller, D.D., see Fedyna, J.S. (135) 161
Mizushima, A., Uchida, S., Zhou, X.-M., Kagiya, T. and Yoshida, H.
Cardiac $M_2$ receptors consist of two different types, both regulated by GTP (135) 403
Monopoli, A., see Rovescalli, A.C. (135) 129
Morel, N., Hardy, J.-P. and Godfraind, T.
Histamine-operated calcium channels in intestinal smooth muscle of the guinea-pig (135) 69
Morton, H.E., see Hall, R.A. (135) 193
Mülsch, A., Böhme, E. and Busse, R.
Stimulation of soluble guanylate cyclase by endothelium-derived relaxing factor from cultured endothelial cells (135) 247
Mulvany, M.J., see Juul, B. (135) 61

Nabeshima, T., Fukaya, H., Yamaguchi, K., Ishikawa, K., Furukawa, H. and Kameyama, T.
Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine (135) 23
Naes, L., see Westfall, T.C. (135) 433
Nakamura, M. and Ferreira, S.H.
A peripheral sympathetic component in inflammatory hyperalgesia (135) 145
Naruse, T. and Asami, T.
Intravenous self-administration of diazepam in rats (135) 365
Nijssen, P.C.G. and Childers, S.R.
Characteristics of sodium-induced increase in opiate antagonist binding sites in rat brain membranes (135) 355
Nishiuchi, Y., see Koyano, K. (135) 337
Nordberg, A., see Zhang, X. (135) 457
Novas, M.L., Medina, J.H., Calvo, D. and De Robertis, E.
Increase of peripheral type benzodiazepine binding sites in kidney and olfactory bulb in acutely stressed rats (135) 243

Okamura, T., see Toda, N. (135) 321
Oliver, D.W., see Venter, D.P. (135) 183
Omini, C., see Berti, F. (135) 375
Ongini, E., see Rovescalli, A.C. (135) 129
Owman, C., see Schmidt, G. (135) 11

Passino, N., see Mereu, G. (135) 453
Pérez, A., see Ureta, H. (135) 289
Peterson, M.R., see Dragunow, M. (135) 113
Pichler, L., Pifl, C., Hornykiewicz, O. and Kobinger, W.
The dopamine autoreceptor agonist B-HT 920 inhibits in vivo dopamine release into the cerebroventricular system of cats (135) 239
Pifl, C., see Pichler, L. (135) 239
Plaznik, A. and Kostowski, W.
The effects of antidepressants and electroconvulsive shocks on the functioning of the mesolimbic dopaminergic system: a behavioral study (135) 389
Poitevin, B., see Davenas, E. (135) 313

Racagni, G., see Rovescalli, A.C. (135) 129
Rangachari, P.K. and McWade, D.
Histamine stimulation of canine colonic epithelium: potentiation by hydroxylamines (135) 331
Regoli, D., see Couture, R. (135) 345
Riffee, W.H., Wanek, E. and Wilcox, R.E.
Prevention of amphetamine-induced behavioral hypersensitivity by concomitant treatment with microgram doses of apomorphine (135) 255
Robertson, H.A., see Dragunow, M. (135) 113
Rodríguez-Puyol, D., see Barrio, V. (135) 93
Rokach, J., see Hall, R.A. (135) 193
Rosen, M.R., see Johnson, N. (135) 41
Rossoni, G., see Berti, F. (135) 375
Rovescalli, A.C., Brunello, N., Monopoli, A., Ongini, E. and Racagni, G.
Absence of [$^3$H]SCH 23390 specific binding sites in anterior pituitary: dissociation from effects on prolactin secretion (135) 129
Rumbach, L., see Micheletti, G. (135) 397

Sakakibara, S., see Koyano, K. (135) 337
Saltarelli, M.D., Lowenstein, P.R. and Coyle, J.T.
Rapid in vitro modulation of [$^3$H]hemicholinium-3 binding sites in rat striatal slices (135) 35
Sasakawa, N., see Ishii, K. (135) 455
Sawamura, A., see Azuma, J. (135) 137
Scheuer, B., see Wessler, I. (135) 85
Schmauss, C. and Herz, A.

Intrathecally administered dynorphin-(1-17) modulates morphine-induced antinociception differently in morphine-naive and morphine-tolerant rats (135) 429
Schmidt, G., Kannisto, P., Owman, C. and Sjöberg, N.-O.
Alteration by histamine of the sympathetic nerve-mediated contractions in the bovine ovarian follicle wall in vitro (135) 11
Sick, P., see Hoang, N.D. (135) 89
Sills, M.A., see Loo, P.A. (135) 261
Singh, L. and Handley, S.L.
Behavioural evidence for an interdependence between $GABA_A$ receptors and $\beta_2$-adrenoceptors (135) 419
Sjöberg, N.-O., see Schmidt, G. (135) 11
Smith, I.C.H., see Amobi, N.I.B. (135) 173
Sortino, M., Canonico, P.L., Summers, S.T. and Cronin, M.J.
Protein kinase C inhibits TRH-stimulated phosphoinositide hydrolysis in $GH_3$ cells [1] (135) 77
Soudijn, W., see Van Amsterdam, J.G.C. (135) 411
Sperelakis, N., see Azuma, J. (135) 137
Spinelli, W., see Johnson, N. (135) 41
Stjernlöf, P., see Zhang, X. (135) 457
Stone, D.M., see Johnson, M. (135) 231
Sulpizio, A. and Hieble, J.P.
Demonstration of $\alpha_2$-adrenoceptor-mediated contraction in the isolated canine saphenous artery treated with Bay K 8644 (135) 107
Summers, S.T., see Sortino, M. (135) 77

Takagi, Y., see Hirata, Y. (135) 439
Takata, S., see Hirata, Y. (135) 439
Takemori, A.E., see Martin, J.R. (135) 203
Ticku, M.K., see Lehoullier, P.F. (135) 235
Toda, N., Bian, K., Akiba, T. and Okamura, T.
Heterogeneity in mechanisms of bradykinin action in canine isolated blood vessels (135) 321
Tondo, C., see Berti, F. (135) 375
Tranchant, C., see Micheletti, G. (135) 397

Uchida, S., see Mizushima, A. (135) 403
Ureta, H., López, L.F., Pérez, A. and Huidobro-Toro, J.P.
κ-Opiate-induced diuresis and changes in blood pressure: demonstration of receptor stereoselectivity using (+)- and (−)-tifluadom (135) 289

Van Amsterdam, J.G.C., Van Buuren, K.J.H., Blad, M.W.M. and Soudijn, W.
Synthesis of enkephalinase B inhibitors, and their activity on isolated enkephalin-degrading enzymes (135) 411
Van Buuren, K.J.H., see Van Amsterdam, J.G.C. (135) 411
Van Calker, D. and Heumann, R.
Nerve growth factor potentiates the agonist-stimulated accumulation of inositol phosphates in PC-12 pheochromocytoma cells (135) 259
Vargaftig, B.B., see Fouque, F. (135) 211
Venter, D.P. and Oliver, D.W.
A model for agonists acting directly as well as indirectly (135) 183
Vergnes, M., see Micheletti, G. (135) 397
Viganó, T., see Berti, F. (135) 375

Wanek, E., see Riffee, W.H. (135) 255
Warter , J.-M., see Micheletti, G. (135) 397
Wei, E.T., see Dashwood, M.R. (135) 111
Wessler, I., Scheuer, B. and Kilbinger, H.
[$^3$H]Acetylcholine release from the phrenic nerve is increased or decreased by activation or desensitization of nicotine receptors (135) 85
Westerink, B.H.C., Damsma, G., De Vries, J.B. and Koning, H.
Dopamine re-uptake inhibitors show inconsistent effects on the in vivo release of dopamine as measured by intracerebral dialysis in the rat (135) 123
Westfall, T.C., Badino, L., Naes, L. and Meldrum, M.J.
Alterations in the field stimulation-induced release of endogenous norepinephrine from the coccygeal artery of spontaneously hypertensive and Wistar-Kyoto rats [1] (135) 433
White, F.J.
D-1 dopamine receptor stimulation enables the inhibition of nucleus accumbens neurons by a D-2 receptor agonist (135) 101
Wilcox, R.E., see Riffee, W.H. (135) 255
Williams, M., see Loo, P.A. (135) 261
Wong, C.-L.
The effect of nalbuphine on gastrointestinal transit in mice (135) 219

Yamaguchi, K., see Nabeshima, T. (135) 23
Yoakim, C., see Hall, R.A. (135) 193
Yoshida, H., see Mizushima, A. (135) 403

Zhang, X., Stjernlöf, P., Adem, A. and Nordberg, A.
Anatoxin-a a potent ligand for nicotinic cholinergic receptors in rat brain (135) 457
Zhou, X.-M., see Mizushima, A. (135) 403

*European Journal of Pharmacology*, 135 (1987) 463–472
Elsevier



# KEYWORD INDEX TO VOLUME

**ACE inhibitor**
Inflammatory response; Ovalbumin; Bradykinin; Capsaicin (Lindgren, B.R. (135) 383)

**Acidosis**
Cerebral artery (middle); Pulmonary artery; α-Adrenoceptor subtypes (Cat, Rabbit) (Medgett, I.C. (135) 443)

**Adrenaline**
Aspirin; Clonidine; PAF-acether; Platelet; Yohimbine (Fouque, F. (135) 211)

**Adrenergic nerves**
Electrical nerve stimulation; Follicular fluid (chemical composition); Ovarian follicle smooth musculature; Histamine; 2-Methylhistamine; 4-Methylhistamine (Schmidt, G. (135) 11)

**Adrenergic responses**
Vas deferens; Non-adrenergic responses; $\alpha_1$-Adrenoceptor potentiation; Nifedipine; Verapamil; Idazoxan (Rat) (Amobi, N.I.B. (135) 173)

**$\alpha_1$-Adrenoceptor potentiation**
Vas deferens; Adrenergic responses; Non-adrenergic responses; Nifedipine; Verapamil; Idazoxan (Rat) (Amobi, N.I.B. (135) 173)

**$\beta_2$-Adrenoceptors**
$GABA_A$ receptors; Head-twitch; 5-Methoxy-N,N-dimethyltryptamine (Tics) (Singh, L. (135) 419)

**α-Adrenoceptor subtypes**
Cerebral artery (middle); Pulmonary artery; Acidosis (Cat, Rabbit) (Medgett, I.C. (135) 443)

**Agonist binding sites (multiple)**
Cardiac $M_2$ receptors; GTP binding proteins (Mizushima, A. (135) 403)

**Amfonelic acid**
Dopamine release; Brain dialysis; Re-uptake blockers; GBR 12909 (Westerink, B.H.C. (135) 123)

**Aminopeptidase**
Enkephalinase; Brain slices; Enkephalin release; Mercaptoacyldipeptides; Metal chelating agents (Rat) (Van Amsterdam, J.G.C. (135) 411)

**Aminopyridines**
Muscle relaxants; Neuromuscular transmission (Biessels, P.T.M. (135) 155)

**Amphetamine**
Dopamine; Morphine; SCH 23390 (Reward) (Leone, P. (135) 251)

**Amphetamine-stimulated locomotor activity**
Apomorphine (Riffee, W.H. (135) 255)

**Angiotensin converting enzyme inhibitor**
Angiotensin II; Angiotensin I; Tachyphylaxis; Endothelium (Juul, B. (135) 61)

**Angiotensin I**
Angiotensin II; Tachyphylaxis; Angiotensin converting enzyme inhibitor; Endothelium (Juul, B. (135) 61)

**Angiotensin II**
Angiotensin I; Tachyphylaxis; Angiotensin converting enzyme inhibitor; Endothelium (Juul, B. (135) 61)

**Antagonism**
Nalbuphine; Gastrointestinal transit; Naloxone; Mr 2266; Opiate receptors (Wong, C.-L. (135) 219)

**Anterior pituitary**
Inositol phopshates; TRH; Protein kinase C; Phorbol esters; $GH_3$ cells (Sortino, M. (135) 77)

SCH 23390; Dopamine receptors; Prolactin (Rovescalli, A.C. (135) 129)

**Antiarrhythmic drugs**
Cellular electrophysiology; Arrhythmogenic mechanisms; Purkinje fibers; Use dependence (Johnson, N. (135) 41)

**Antiaversive effect**
Midbrain; Central grey; Brain electrical stimulation; $GABA_A$ receptor agonists; Baclofen (Intracerebral microinjection) (Audi, E.A. (135) 225)

**Antidepressant drugs**
Nucleus accumbens; Dopaminergic agonists; Electroconvulsive shocks, Microinjection study; Behavior (Rat) (Plaznik, A. (135) 389)

**Apomorphine**
Amphetamine-stimulated locomotor activity (Riffee, W.H. (135) 255)

**Arrhythmogenic mechanisms**
Cellular electrophysiology; Antiarrhythmic drugs; Purkinje fibers; Use dependence (Johnson, N. (135) 41)

**Arterial postjunctional $\alpha_2$-adrenoceptors**
Saphenous artery (Canine) (Sulpizio, A. (135) 107)

**Aspirin**
Adrenaline; Clonidine; PAF-acether; Platelet; Yohimbine (Fouque, F. (135) 211)

**Atrial natriuretic peptide**
Glomeruli (isolated); Glomerular cross-sectional area; Glomerular filtration surface; Ultrafiltration coefficient; PAF (Rat) (Barrio, V. (135) 93)

Vascular smooth muscle cells; Receptor down-regulation; cGMP (Hirata, Y. (135) 439)

**Baclofen**
Midbrain; Central grey; Brain electrical stimulation; Antiaversive effect; $GABA_A$ receptor agonists (Intracerebral microinjection) (Audi, E.A. (135) 225)

**BAY K-8644**
Neurotensin; Intestine; $Ca^{2+}$ channels; $Ca^{2+}$ transport (Kullak, A. (135) 297)

**Behavior**
Nucleus accumbens; Dopaminergic agonists; Antidepressant drugs; Electroconvulsive shocks, Microinjection study (Rat) (Plaznik, A. (135) 389)

**Benzodiazepine receptor (peripheral type)**
Receptor regulation; RO 5-4864; Stress (acute) (Novas, M.L. (135) 243)

**Benzodiazepines**
Photoaffinity labeling (Receptors) (Barrio, V. (135) 97)

Spinal cord (cultured neurons); GABA; $^{36}$Cl-influx; $\beta$-Carbolines (Lehoullier, P.F. (135) 235)

**$\beta$-Blocker analgesia**
Sympathetic hyperalgesia; Dopamine hyperalgesia; SCH 23390 analgesia; Sympathetic pain (Nakamura, M. (135) 145)

**Blood pressure**
Substance P analogues; Spinal action; Heart rate; Catecholaminergic mechanism (Spinal cord transection) (Couture, R. (135) 345)

**Bradykinin**
Endothelial cells (cultured); Endothelium-derived relaxing factor; Thimerosal; Gossypol; Guanylate cyclase (soluble) (Mülsch, A. (135) 247)

ACE inhibitor; Inflammatory response; Ovalbumin; Capsaicin (Lindgren, B.R. (135) 383)

**Bradykinin action**
EDRF; Prostaglandin $I_2$; Endothelium (Toda, N. (135) 321)

**Brain dialysis**
Dopamine release; Re-uptake blockers; Amfonelic acid; GBR 12909 (Westerink, B.H.C. (135) 123)

**Brain electrical stimulation**
Midbrain; Central grey; Antiaversive effect; $GABA_A$ receptor agonists; Baclofen (Intracerebral microinjection) (Audi, E.A. (135) 225)

**Brain phenolamines**
Triethyltin; Enzymes (Rat) (Coulon, J.F. (135) 53)

**Brain slices**
Enkephalinase; Aminopeptidase; Enkephalin release; Mercaptoacyldipeptides; Metal chelating agents (Rat) (Van Amsterdam, J.G.C. (135) 411)

**Brain synaptoneurosomes**
GABA receptors; Chloride channel; Chloride efflux; Pentobarbital; GABA mimetics; Foot shock stress (Concas, A. (135) 423)

**$Ca^{2+}$ channel**
$\omega$-Conotoxin; Sympathetic ganglion; Neuromuscular junction; Electric organ; Transmitter release (Koyano, K. (135) 337)

**$Ca^{2+}$ channels**
Neurotensin; Intestine; BAY K-8644; $Ca^{2+}$ transport (Kullak, A. (135) 297)

**Calcitonin gene-related peptide**
Guinea-pig ileum longitudinal muscle (Relaxation, Contraction) (Barthó, L. (135) 449)

**Calcium entry blockers**
Histamine; Smooth muscle (Morel, N. (135) 69)

**Calcium slow channels**
Inotropic action (positive); Cyclic AMP; Hydralazine; Histamine; Cardiac electrophysiology (Azuma, J. (135) 137)

**Capsaicin**
ACE inhibitor; Inflammatory response; Ovalbumin; Bradykinin (Lindgren, B.R. (135) 383)

**$\beta$-Carbolines**
Spinal cord (cultured neurons); GABA; $^{36}$Cl-influx; Benzodiazepines (Lehoullier, P.F. (135) 235)

**Cardiac electrophysiology**
Inotropic action (positive); Calcium slow channels; Cyclic AMP; Hydralazine; Histamine (Azuma, J. (135) 137)

**Cardiac $M_2$ receptors**
Agonist binding sites (multiple); GTP binding proteins (Mizushima, A. (135) 403)

**Catecholaminergic mechanism**
Substance P analogues; Spinal action; Blood pressure; Heart rate (Spinal cord transection) (Couture, R. (135) 345)

**$Ca^{2+}$ transport**
Neurotensin; Intestine; $Ca^{2+}$ channels; BAY K-8644 (Kullak, A. (135) 297)

**Caudal artery**
Norepinephrine; Spontaneously hypertensive rats; Wistar-Kyoto rats; Noradrenergic transmission; Hypertension (Westfall, T.C. (135) 433)

**Cellular electrophysiology**
Antiarrhythmic drugs; Arrhythmogenic mechanisms; Purkinje fibers; Use dependence (Johnson, N. (135) 41)

**Central grey**
Midbrain; Brain electrical stimulation; Antiaversive effect; $GABA_A$ receptor agonists; Baclofen (Intracerebral microinjection) (Audi, E.A. (135) 225)

**Cerebral artery (middle)**
Pulmonary artery; Acidosis; $\alpha$-Adrenoceptor subtypes (Cat, Rabbit) (Medgett, I.C. (135) 443)

**Chloride channel**
GABA receptors; Chloride efflux; Brain synaptoneurosomes; Pentobarbital; GABA mimetics; Foot shock stress (Concas, A. (135) 423)

**Chloride efflux**
GABA receptors; Chloride channel; Brain synaptoneurosomes; Pentobarbital; GABA mimetics; Foot shock stress (Concas, A. (135) 423)

**Climbing behavior**
Dopamine agonists; Opiates; Haloperidol; Lithium; Dopamine receptors (Martin, J.R. (135) 203)

**$^{36}Cl$-influx**
Spinal cord (cultured neurons); GABA; Benzodiazepines; $\beta$-Carbolines (Lehoullier, P.F. (135) 235)

**Clonidine**
Adrenaline; Aspirin; PAF-acether; Platelet; Yohimbine (Fouque, F. (135) 211)

**Colonic mucosa**
Histamine; Hydroxylamines; Short-circuit currents (Dog) (Rangachari, P.K. (135) 331)

**$\omega$-Conotoxin**
Sympathetic ganglion; Neuromuscular junction; Electric organ; Transmitter release; $Ca^{2+}$ channel (Koyano, K. (135) 337)

**Coronary arteries (isolated)**
Serotonin receptors; $\beta$-Methyldigoxin; Coronary spasm (Hoang, N.D. (135) 89)

**Coronary spasm**
Coronary arteries (isolated); Serotonin receptors; $\beta$-Methyldigoxin (Hoang, N.D. (135) 89)

**Cyclic AMP**
Inotropic action (positive); Calcium slow channels; Hydralazine; Histamine; Cardiac electrophysiology (Azuma, J. (135) 137)

**Defibrotide**
Myocardial ischemia; Prostaglandins; Indomethacin (Berti, F. (135) 375)

**Desensitization**
Motor nerve; [$^3$H]Acetylcholine release; Nicotine receptors (Positive feedback) (Wessler, I. (135) 85)

**Diazepam**
Reinforcer; Self-administration (i.v.) (Rat) (Naruse, T. (135) 365)

**Direct-indirect action**
Receptor model; Molecular pharmacology; D(−) noradrenaline; D(−)norephedrine (Venter, D.P. (135) 183)

**D(−)noradrenaline**
Receptor model; Molecular pharmacology; Direct-indirect action; D(−)norephedrine (Venter, D.P. (135) 183)

**D(−)norephedrine**
Receptor model; Molecular pharmacology; Direct-indirect action; D(−)noradrenaline (Venter, D.P. (135) 183)

**Dopamine**
6-Hydroxydopamine; Methamphetamine; Neurotoxicity; Tryptophan hydroxylase (Johnson, M. (135) 231)

Morphine; Amphetamine; SCH 23390 (Reward) (Leone, P. (135) 251)

**Dopamine agonists**
Climbing behavior; Opiates; Haloperidol; Lithium; Dopamine receptors (Martin, J.R. (135) 203)

**Dopamine autoreceptors**
B-HT 920; Dopamine release; Huntington's disease; Mania; Schizophrenia (Pichler, L. (135) 239)

**Dopamine-dependent behaviour**
D-1 receptors; D-2 receptors; Nucleus accumbens; SKF 38393; Quinpirole (White, F.J. (135) 101)

**Dopamine hyperalgesia**
Sympathetic hyperalgesia; $\beta$-Blocker analgesia; SCH 23390 analgesia; Sympathetic pain (Nakamura, M. (135) 145)

**Dopamine receptors**
SCH 23390; Anterior pituitary; Prolactin (Rovescalli, A.C. (135) 129)

Climbing behavior; Dopamine agonists; Opiates; Haloperidol; Lithium (Martin, J.R. (135) 203)

**Dopamine release**
Brain dialysis; Re-uptake blockers; Amfonelic acid; GBR 12909 (Westerink, B.H.C. (135) 123)

B-HT 920; Dopamine autoreceptors; Huntington's disease; Mania; Schizophrenia (Pichler, L. (135) 239)

**Dopaminergic agonists**
Nucleus accumbens; Antidepressant drugs; Electroconvulsive shocks, Microinjection study; Behavior (Rat) (Plaznik, A. (135) 389)

**D-1 receptors**
D-2 receptors; Nucleus accumbens; Dopamine-dependent behaviour; SKF 38393; Quinpirole (White, F.J. (135) 101)

**D-2 receptors**
D-1 receptors; Nucleus accumbens; Dopamine-dependent behaviour; SKF 38393; Quinpirole (White, F.J. (135) 101)

**Drug antagonism**
Vasopressins; Phosphoinositides; Muscle (smooth, vascular) (Endogenous substances, Receptors) (Fox, A.W. (135) 1)

**Dynorphin**
Spinal analgesia; Morphine; Morphine tolerance (Schmauss, C. (135) 429)

**EDRF**
Bradykinin action; Prostaglandin $I_2$; Endothelium (Toda, N. (135) 321)

**Electrical nerve stimulation**
Adrenergic nerves; Follicular fluid (chemical composition); Ovarian follicle smooth musculature; Histamine; 2-Methylhistamine; 4-Methylhistamine (Schmidt, G. (135) 11)

**Electric organ**
$\omega$-Conotoxin; Sympathetic ganglion; Neuromuscular junction; Transmitter release; $Ca^{2+}$ channel (Koyano, K. (135) 337)

**Electroconvulsive shocks, Microinjection study**
Nucleus accumbens; Dopaminergic agonists; Antidepressant drugs; Behavior (Rat) (Plaznik, A. (135) 389)

**Endothelial cells (cultured)**
Endothelium-derived relaxing factor; Thimerosal; Bradykinin; Gossypol; Guanylate cyclase (soluble) (Mülsch, A. (135) 247)

**Endothelium**
Angiotensin II; Angiotensin I; Tachyphylaxis; Angiotensin converting enzyme inhibitor (Juul, B. (135) 61)

Bradykinin action; EDRF; Prostaglandin $I_2$ (Toda, N. (135) 321)

**Endothelium-derived relaxing factor**
Endothelial cells (cultured); Thimerosal; Bradykinin; Gossypol; Guanylate cyclase (soluble) (Mülsch, A. (135) 247)

**Endotoxin shock**
PAF; PAF antagonists; WEB 2086 (Casals-Stenzel, J. (135) 117)

**Enkephalinase**
Brain slices; Aminopeptidase; Enkephalin release; Mercaptoacyldipeptides; Metal chelating agents (Rat) (Van Amsterdam, J.G.C. (135) 411)

**Enkephalin release**
Enkephalinase; Brain slices; Aminopeptidase; Mercaptoacyldipeptides; Metal chelating agents (Rat) (Van Amsterdam, J.G.C. (135) 411)

**Enzymes**
Triethyltin; Brain phenolamines (Rat) (Coulon, J.F. (135) 53)

**Epilepsy**
$\alpha$-Noradrenergic transmission; Spontaneous petit mal-like seizures (Rat) (Micheletti, G. (135) 397)

**N-Ethylmaleimide**
Opiate receptors; Naloxone; Sodium; Phospholipase $A_2$ (Nijssen, P.C.G. (135) 355)

**Follicular fluid (chemical composition)**
Electrical nerve stimulation; Adrenergic nerves; Ovarian follicle smooth musculature; Histamine; 2-Methylhistamine; 4-Methylhistamine (Schmidt, G. (135) 11)

**Foot shock stress**
GABA receptors; Chloride channel; Chloride efflux; Brain synaptoneurosomes; Pentobarbital; GABA mimetics (Concas, A. (135) 423)

**GABA**
Spinal cord (cultured neurons); $^{36}Cl$-influx; Benzodiazepines; $\beta$-Carbolines (Lehoullier, P.F. (135) 235)

**GABA mimetics**
GABA receptors; Chloride channel; Chloride efflux; Brain synaptoneurosomes; Pentobarbital; Foot shock stress (Concas, A. (135) 423)

**$GABA_A$ receptor agonists**
Midbrain; Central grey; Brain electrical stimulation; Antiaversive effect; Baclofen (Intracerebral microinjection) (Audi, E.A. (135) 225)

**$GABA_A$ receptors**
$\beta_2$-Adrenoceptors; Head-twitch; 5-Methoxy-N,N-dimethyltryptamine (Tics) (Singh, L. (135) 419)

**GABA receptors**
Chloride channel; Chloride efflux; Brain synaptoneurosomes; Pentobarbital; GABA mimetics; Foot shock stress (Concas, A. (135) 423)

**Gastrointestinal transit**
Nalbuphine; Naloxone; Mr 2266; Opiate receptors; Antagonism (Wong, C.-L. (135) 219)

**GBR 12909**
Dopamine release; Brain dialysis; Re-uptake blockers; Amfonelic acid (Westerink, B.H.C. (135) 123)

**$GH_3$ cells**
Inositol phopshates; Anterior pituitary; TRH; Protein kinase C; Phorbol esters (Sortino, M. (135) 77)

**Glomerular cross-sectional area**
Glomeruli (isolated); Glomerular filtration surface; Ultrafiltration coefficient; PAF; Atrial natriuretic peptide (Rat) (Barrio, V. (135) 93)

**Glomerular filtration surface**
Glomeruli (isolated); Glomerular cross-sectional area; Ultrafiltration coefficient; PAF; Atrial natriuretic peptide (Rat) (Barrio, V. (135) 93)

**Glomeruli (isolated)**
Glomerular cross-sectional area; Glomerular filtration surface; Ultrafiltration coefficient; PAF; Atrial natriuretic peptide (Rat) (Barrio, V. (135) 93)

**cGMP**
Atrial natriuretic peptide; Vascular smooth muscle cells; Receptor down-regulation (Hirata, Y. (135) 439)

**Gossypol**
Endothelial cells (cultured); Endothelium-derived relaxing factor; Thimerosal; Bradykinin; Guanylate cyclase (soluble) (Mülsch, A. (135) 247)

**GTP binding proteins**
Cardiac $M_2$ receptors; Agonist binding sites (multiple) (Mizushima, A. (135) 403)

**Guanylate cyclase (soluble)**
Endothelial cells (cultured); Endothelium-derived relaxing factor; Thimerosal; Bradykinin; Gossypol (Mülsch, A. (135) 247)

**Guinea-pig ileum longitudinal muscle**
Calcitonin gene-related peptide (Relaxation, Contraction) (Barthó, L. (135) 449)

**[$^3$H]Acetylcholine release**
Motor nerve; Nicotine receptors; Desensitization (Positive feedback) (Wessler, I. (135) 85)

**Haloperidol**
Climbing behavior; Dopamine agonists; Opiates; Lithium; Dopamine receptors (Martin, J.R. (135) 203)

**Head-twitch**
$GABA_A$ receptors; $\beta_2$-Adrenoceptors; 5-Methoxy-N,N-dimethyltryptamine (Tics) (Singh, L. (135) 419)

**Heart rate**
Substance P analogues; Spinal action; Blood pressure; Catecholaminergic mechanism (Spinal cord transection) (Couture, R. (135) 345)

**[$^3$H]Hemicholinium-3**
High affinity choline uptake; Striatum (In vitro regulation) (Saltarelli, M.D. (135) 35)

**High affinity choline uptake**
[$^3$H]Hemicholinium-3; Striatum (In vitro regulation) (Saltarelli, M.D. (135) 35)

**Histamine**
Electrical nerve stimulation; Adrenergic nerves; Follicular fluid (chemical composition); Ovarian follicle smooth musculature; 2-Methylhistamine; 4-Methylhistamine (Schmidt, G. (135) 11)

Calcium entry blockers; Smooth muscle (Morel, N. (135) 69)

Inotropic action (positive); Calcium slow channels; Cyclic AMP; Hydralazine; Cardiac electrophysiology (Azuma, J. (135) 137)

Hydroxylamines; Short-circuit currents; Colonic mucosa (Dog) (Rangachari, P.K. (135) 331)

**B-HT 920**
Dopamine release; Dopamine autoreceptors; Huntington's disease; Mania; Schizophrenia (Pichler, L. (135) 239)

**$5HT_{1B}$ receptors**
Penile erections; Serotonin-mimetic compounds; Serotonin receptor antagonists; Serotonin uptake inhibitors; Yawning (Berendsen, H.H.G. (135) 279)

**Huntington's disease**
B-HT 920; Dopamine release; Dopamine autoreceptors; Mania; Schizophrenia (Pichler, L. (135) 239)

**Hydralazine**
Inotropic action (positive); Calcium slow channels; Cyclic AMP; Histamine; Cardiac electrophysiology (Azuma, J. (135) 137)

**6-Hydroxydopamine**
Dopamine; Methamphetamine; Neurotoxicity; Tryptophan hydroxylase (Johnson, M. (135) 231)

**Hydroxylamines**
Histamine; Short-circuit currents; Colonic mucosa (Dog) (Rangachari, P.K. (135) 331)

**Hypertension**
Norepinephrine; Caudal artery; Spontaneously hypertensive rats; Wistar-Kyoto rats; Noradrenergic transmission (Westfall, T.C. (135) 433)

**Idazoxan**
Vas deferens; Adrenergic responses; Non-adrenergic responses; $\alpha_1$-Adrenoceptor potentiation; Nifedipine; Verapamil (Rat) (Amobi, N.I.B. (135) 173)

**Indomethacin**
Myocardial ischemia; Defibrotide; Prostaglandins (Berti, F. (135) 375)

**Inflammation**
Peritoneal macrophages; Silica; Paf-acether (Davenas, E. (135) 313)

**Inflammatory response**
ACE inhibitor; Ovalbumin; Bradykinin; Capsaicin (Lindgren, B.R. (135) 383)

**Inositol phopshates**
Anterior pituitary; TRH; Protein kinase C; Phorbol esters; $GH_3$ cells (Sortino, M. (135) 77)

**Inotropic action (positive)**
Calcium slow channels; Cyclic AMP; Hydralazine; Histamine; Cardiac electrophysiology (Azuma, J. (135) 137)

**Insulin secretion**
Pancreas; Neuropeptide Y; Somatostatin (Isolated islets, Rat) (Alwmark, A. (135) 307)

**Intestine**
Neurotensin; $Ca^{2+}$ channels; BAY K-8644; $Ca^{2+}$ transport (Kullak, A. (135) 297)

**Lithium**
Climbing behavior; Dopamine agonists; Opiates; Haloperidol; Dopamine receptors (Martin, J.R. (135) 203)

**Mania**
B-HT 920; Dopamine release; Dopamine autoreceptors; Huntington's disease; Schizophrenia (Pichler, L. (135) 239)

**Mercaptoacyldipeptides**
Enkephalinase; Brain slices; Aminopeptidase; Enkephalin release; Metal chelating agents (Rat) (Van Amsterdam, J.G.C. (135) 411)

**Metal chelating agents**
Enkephalinase; Brain slices; Aminopeptidase; Enkephalin release; Mercaptoacyldipeptides (Rat) (Van Amsterdam, J.G.C. (135) 411)

**Methamphetamine**
Dopamine; 6-Hydroxydopamine; Neurotoxicity; Tryptophan hydroxylase (Johnson, M. (135) 231)

**5-Methoxy-N,N-dimethyltryptamine**
$GABA_A$ receptors; $\beta_2$-Adrenoceptors; Head-twitch (Tics) (Singh, L. (135) 419)

**$\beta$-Methyldigoxin**
Coronary arteries (isolated); Serotonin receptors; Coronary spasm (Hoang, N.D. (135) 89)

**2-Methylhistamine**
Electrical nerve stimulation; Adrenergic nerves; Follicular fluid (chemical composition); Ovarian follicle smooth musculature; Histamine; 4-Methylhistamine (Schmidt, G. (135) 11)

**4-Methylhistamine**
Electrical nerve stimulation; Adrenergic nerves; Follicular fluid (chemical composition); Ovarian follicle smooth musculature; Histamine; 2-Methylhistamine (Schmidt, G. (135) 11)

**Midbrain**
Central grey; Brain electrical stimulation; Antiaversive effect; $GABA_A$ receptor agonists; Baclofen (Intracerebral microinjection) (Audi, E.A. (135) 225)

**Molecular pharmacology**
Receptor model; Direct-indirect action; D(−)noradrenaline; D(−)norephedrine (Venter, D.P. (135) 183)

**Morphine**
Dopamine; Amphetamine; SCH 23390 (Reward) (Leone, P. (135) 251)

Spinal analgesia; Dynorphin; Morphine tolerance (Schmauss, C. (135) 429)

**Morphine tolerance**
Spinal analgesia; Dynorphin; Morphine (Schmauss, C. (135) 429)

**Motor nerve**
[$^3$H]Acetylcholine release; Nicotine receptors; Desensitization (Positive feedback) (Wessler, I. (135) 85)

**Mr 2266**
Nalbuphine; Gastrointestinal transit; Naloxone; Opiate receptors; Antagonism (Wong, C.-L. (135) 219)

**Muscle relaxants**
Aminopyridines; Neuromuscular transmission (Biessels, P.T.M. (135) 155)

**Muscle (smooth, vascular)**
Vasopressins; Phosphoinositides; Drug antagonism (Endogenous substances, Receptors) (Fox, A.W. (135) 1)

**Myocardial ischemia**
Defibrotide; Prostaglandins; Indomethacin (Berti, F. (135) 375)

**Nalbuphine**
Gastrointestinal transit; Naloxone; Mr 2266; Opiate receptors; Antagonism (Wong, C.-L. (135) 219)

**Naloxone**
Nalbuphine; Gastrointestinal transit; Mr 2266; Opiate receptors; Antagonism (Wong, C.-L. (135) 219)

Opiate receptors; Sodium; N-Ethylmaleimide; Phospholipase $A_2$ (Nijssen, P.C.G. (135) 355)

**Naloxone antagonism**
Tifluadom; κ-Opiate receptor; Opiate stereoselectivity (κ-Opiate vascular effects, κ-Opiate-induced diuresis) (Ureta, H. (135) 289)

**Neuromuscular junction**
ω-Conotoxin; Sympathetic ganglion; Electric organ; Transmitter release; $Ca^{2+}$ channel (Koyano, K. (135) 337)

**Neuromuscular transmission**
Aminopyridines; Muscle relaxants (Biessels, P.T.M. (135) 155)

**Neuropeptide Y**
Insulin secretion; Pancreas; Somatostatin (Isolated islets, Rat) (Alwmark, A. (135) 307)

**Neurotensin**
Intestine; $Ca^{2+}$ channels; BAY K-8644; $Ca^{2+}$ transport (Kullak, A. (135) 297)

**Neurotoxicity**
Dopamine; 6-Hydroxydopamine; Methamphetamine; Tryptophan hydroxylase (Johnson, M. (135) 231)

**Nicotine receptors**
Motor nerve; [$^3$H]Acetylcholine release; Desensitization (Positive feedback) (Wessler, I. (135) 85)

**Nifedipine**
Vas deferens; Adrenergic responses; Non-adrenergic responses; $\alpha_1$-Adrenoceptor potentiation; Verapamil; Idazoxan (Rat) (Amobi, N.I.B. (135) 173)

**Non-adrenergic responses**
Vas deferens; Adrenergic responses; $\alpha_1$-Adrenoceptor potentiation; Nifedipine; Verapamil; Idazoxan (Rat) (Amobi, N.I.B. (135) 173)

**Noradrenergic transmission**
Norepinephrine; Caudal artery; Spontaneously hypertensive rats; Wistar-Kyoto rats; Hypertension (Westfall, T.C. (135) 433)

**α-Noradrenergic transmission**
Spontaneous petit mal-like seizures; Epilepsy (Rat) (Micheletti, G. (135) 397)

**Norepinephrine**
Caudal artery; Spontaneously hypertensive rats; Wistar-Kyoto rats; Noradrenergic transmission; Hypertension (Westfall, T.C. (135) 433)

**Nucleus accumbens**
D-1 receptors; D-2 receptors; Dopamine-dependent behaviour; SKF 38393; Quinpirole (White, F.J. (135) 101)

Dopaminergic agonists; Antidepressant drugs; Electroconvulsive shocks, Microinjection study; Behavior (Rat) (Plaznik, A. (135) 389)

**κ-Opiate receptor**
Tifluadom; Opiate stereoselectivity; Naloxone antagonism (κ-Opiate vascular effects, κ-Opiate-induced diuresis) (Ureta, H. (135) 289)

**Opiate receptors**
Nalbuphine; Gastrointestinal transit; Naloxone; Mr 2266; Antagonism (Wong, C.-L. (135) 219)

Naloxone; Sodium; N-Ethylmaleimide; Phospholipase $A_2$ (Nijssen, P.C.G. (135) 355)

**Opiates**
Climbing behavior; Dopamine agonists; Haloperidol; Lithium; Dopamine receptors (Martin, J.R. (135) 203)

**Opiate stereoselectivity**
Tifluadom; κ-Opiate receptor; Naloxone antagonism (κ-Opiate vascular effects, κ-Opiate-induced diuresis) (Ureta, H. (135) 289)

**Ovalbumin**
ACE inhibitor; Inflammatory response; Bradykinin; Capsaicin (Lindgren, B.R. (135) 383)

**Ovarian follicle smooth musculature**
Electrical nerve stimulation; Adrenergic nerves; Follicular fluid (chemical composition); Histamine; 2-Methylhistamine; 4-Methylhistamine (Schmidt, G. (135) 11)

**PAF**
Glomeruli (isolated); Glomerular cross-sectional area; Glomerular filtration surface; Ultrafiltration coefficient; Atrial natriuretic peptide (Rat) (Barrio, V. (135) 93)

PAF antagonists; WEB 2086; Endotoxin shock (Casals-Stenzel, J. (135) 117)

**PAF-acether**
Adrenaline; Aspirin; Clonidine; Platelet; Yohimbine (Fouque, F. (135) 211)

**Paf-acether**
Peritoneal macrophages; Silica; Inflammation (Davenas, E. (135) 313)

**PAF antagonists**
PAF; WEB 2086; Endotoxin shock (Casals-Stenzel, J. (135) 117)

**Pancreas**
Insulin secretion; Neuropeptide Y; Somatostatin (Isolated islets, Rat) (Alwmark, A. (135) 307)

**Penile erections**
$5HT_{1B}$ receptors; Serotonin-mimetic compounds; Serotonin receptor antagonists; Serotonin uptake inhibitors; Yawning (Berendsen, H.H.G. (135) 279)

**Pentobarbital**
GABA receptors; Chloride channel; Chloride efflux; Brain synaptoneurosomes; GABA mimetics; Foot shock stress (Concas, A. (135) 423)

**Peritoneal macrophages**
Silica; Paf-acether; Inflammation (Davenas, E. (135) 313)

**Phencyclidine**
Tolerance; Supersensitivity; Stereotyped behavior (Repeated administration) (Nabeshima, T. (135) 23)

**Phorbol esters**
Inositol phopshates; Anterior pituitary; TRH; Protein kinase C; $GH_3$ cells (Sortino, M. (135) 77)

**Phosphoinositides**
Vasopressins; Drug antagonism; Muscle (smooth, vascular) (Endogenous substances, Receptors) (Fox, A.W. (135) 1)

**Phospholipase $A_2$**
Opiate receptors; Naloxone; Sodium; N-Ethylmaleimide (Nijssen, P.C.G. (135) 355)

**Photoaffinity labeling**
Benzodiazepines (Receptors) (Barrio, V. (135) 97)

**Platelet**
Adrenaline; Aspirin; Clonidine; PAF-acether; Yohimbine (Fouque, F. (135) 211)

**Platelet aggregation**
Thromboxane antagonists; Thromboxane $A_2$; Prostaglandin endoperoxides (Hall, R.A. (135) 193)

**Prolactin**
SCH 23390; Dopamine receptors; Anterior pituitary (Rovescalli, A.C. (135) 129)

**Prostaglandin endoperoxides**
Thromboxane antagonists; Thromboxane $A_2$; Platelet aggregation (Hall, R.A. (135) 193)

**Prostaglandin $I_2$**
Bradykinin action; EDRF; Endothelium (Toda, N. (135) 321)

**Prostaglandins**
Myocardial ischemia; Defibrotide; Indomethacin (Berti, F. (135) 375)

**Protein kinase C**
Inositol phopshates; Anterior pituitary; TRH; Phorbol esters; $GH_3$ cells (Sortino, M. (135) 77)

**Pulmonary artery**
Cerebral artery (middle); Acidosis; $\alpha$-Adrenoceptor subtypes (Cat, Rabbit) (Medgett, I.C. (135) 443)

**Purkinje fibers**
Cellular electrophysiology; Antiarrhythmic drugs; Arrhythmogenic mechanisms; Use dependence (Johnson, N. (135) 41)

**Quinpirole**
D-1 receptors; D-2 receptors; Nucleus accumbens; Dopamine-dependent behaviour; SKF 38393 (White, F.J. (135) 101)

**Receptor down-regulation**
Atrial natriuretic peptide; Vascular smooth muscle cells; cGMP (Hirata, Y. (135) 439)

**Receptor model**
Molecular pharmacology; Direct-indirect action; D(−)noradrenaline; D(−)norephedrine (Venter, D.P. (135) 183)

**Receptor regulation**
Benzodiazepine receptor (peripheral type); RO 5-4864; Stress (acute) (Novas, M.L. (135) 243)

**Reinforcer**
Diazepam; Self-administration (i.v.) (Rat) (Naruse, T. (135) 365)

**Re-uptake blockers**
Dopamine release; Brain dialysis; Amfonelic acid; GBR 12909 (Westerink, B.H.C. (135) 123)

**RO 5-4864**
Benzodiazepine receptor (peripheral type); Receptor regulation; Stress (acute) (Novas, M.L. (135) 243)

**Saphenous artery**
Arterial postjunctional $\alpha_2$-adrenoceptors (Canine) (Sulpizio, A. (135) 107)

**SCH 23390**
Dopamine receptors; Anterior pituitary; Prolactin (Rovescalli, A.C. (135) 129)

Dopamine; Morphine; Amphetamine (Reward) (Leone, P. (135) 251)

**SCH 23390 analgesia**
Sympathetic hyperalgesia; Dopamine hyperalgesia; $\beta$-Blocker analgesia; Sympathetic pain (Nakamura, M. (135) 145)

**Schizophrenia**
B-HT 920; Dopamine release; Dopamine autoreceptors; Huntington's disease; Mania (Pichler, L. (135) 239)

**$\beta_2/\beta_1$-Selectivity ratio**
Trimetoquinol; Tetrahydroisoquinolines; Thromboxane $A_2$ antagonism; Trimetoquinol analogues (N-substituted) (Fedyna, J.S. (135) 161)

**Self-administration (i.v.)**
Diazepam; Reinforcer (Rat) (Naruse, T. (135) 365)

**Serotonin-mimetic compounds**
$5HT_{1B}$ receptors; Penile erections; Serotonin receptor antagonists; Serotonin uptake inhibitors; Yawning (Berendsen, H.H.G. (135) 279)

**Serotonin receptor antagonists**
$5HT_{1B}$ receptors; Penile erections; Serotonin-mimetic compounds; Serotonin uptake inhibitors; Yawning (Berendsen, H.H.G. (135) 279)

**Serotonin receptors**
Coronary arteries (isolated); $\beta$-Methyldigoxin; Coronary spasm (Hoang, N.D. (135) 89)

**Serotonin uptake inhibitors**
$5HT_{1B}$ receptors; Penile erections; Serotonin-mimetic compounds; Serotonin receptor antagonists; Yawning (Berendsen, H.H.G. (135) 279)

**Short-circuit currents**
Histamine; Hydroxylamines; Colonic mucosa (Dog) (Rangachari, P.K. (135) 331)

**Silica**
Peritoneal macrophages; Paf-acether; Inflammation (Davenas, E. (135) 313)

**SKF 38393**
D-1 receptors; D-2 receptors; Nucleus accumbens; Dopamine-dependent behaviour; Quinpirole (White, F.J. (135) 101)

**Smooth muscle**
Histamine; Calcium entry blockers (Morel, N. (135) 69)

**Sodium**
Opiate receptors; Naloxone; N-Ethylmaleimide; Phospholipase $A_2$ (Nijssen, P.C.G. (135) 355)

**Somatostatin**
Insulin secretion; Pancreas; Neuropeptide Y (Isolated islets, Rat) (Alwmark, A. (135) 307)

**Spinal action**
Substance P analogues; Blood pressure; Heart rate; Catecholaminergic mechanism (Spinal cord transection) (Couture, R. (135) 345)

**Spinal analgesia**
Dynorphin; Morphine; Morphine tolerance (Schmauss, C. (135) 429)

**Spinal cord (cultured neurons)**
GABA; $^{36}Cl$-influx; Benzodiazepines; $\beta$-Carbolines (Lehoullier, P.F. (135) 235)

**Spontaneously hypertensive rats**
Norepinephrine; Caudal artery; Wistar-Kyoto rats; Noradrenergic transmission; Hypertension (Westfall, T.C. (135) 433)

**Spontaneous petit mal-like seizures**
$\alpha$-Noradrenergic transmission; Epilepsy (Rat) (Micheletti, G. (135) 397)

**Stereotyped behavior**
Phencyclidine; Tolerance; Supersensitivity (Repeated administration) (Nabeshima, T. (135) 23)

**Stress (acute)**
Benzodiazepine receptor (peripheral type); Receptor regulation; RO 5-4864 (Novas, M.L. (135) 243)

**Striatum**
[$^3$H]Hemicholinium-3; High affinity choline uptake (In vitro regulation) (Saltarelli, M.D. (135) 35)

**Substance P analogues**
Spinal action; Blood pressure; Heart rate; Catecholaminergic mechanism (Spinal cord transection) (Couture, R. (135) 345)

**Supersensitivity**
Phencyclidine; Tolerance; Stereotyped behavior (Repeated administration) (Nabeshima, T. (135) 23)

**Sympathetic ganglion**
$\omega$-Conotoxin; Neuromuscular junction; Electric organ; Transmitter release; $Ca^{2+}$ channel (Koyano, K. (135) 337)

**Sympathetic hyperalgesia**
Dopamine hyperalgesia; $\beta$-Blocker analgesia; SCH 23390 analgesia; Sympathetic pain (Nakamura, M. (135) 145)

**Sympathetic pain**
Sympathetic hyperalgesia; Dopamine hyperalgesia; β-Blocker analgesia; SCH 23390 analgesia (Nakamura, M. (135) 145)

**Tachyphylaxis**
Angiotensin II; Angiotensin I; Angiotensin converting enzyme inhibitor; Endothelium (Juul, B. (135) 61)

**Tetrahydroisoquinolines**
Trimetoquinol; $\beta_2/\beta_1$-Selectivity ratio; Thromboxane $A_2$ antagonism; Trimetoquinol analogues (N-substituted) (Fedyna, J.S. (135) 161)

**Thimerosal**
Endothelial cells (cultured); Endothelium-derived relaxing factor; Bradykinin; Gossypol; Guanylate cyclase (soluble) (Mülsch, A. (135) 247)

**Thromboxane $A_2$**
Thromboxane antagonists; Prostaglandin endoperoxides; Platelet aggregation (Hall, R.A. (135) 193)

**Thromboxane $A_2$ antagonism**
Trimetoquinol; Tetrahydroisoquinolines; $\beta_2/\beta_1$-Selectivity ratio; Trimetoquinol analogues (N-substituted) (Fedyna, J.S. (135) 161)

**Thromboxane antagonists**
Thromboxane $A_2$; Prostaglandin endoperoxides; Platelet aggregation (Hall, R.A. (135) 193)

**Tifluadom**
κ-Opiate receptor; Opiate stereoselectivity; Naloxone antagonism (κ-Opiate vascular effects, κ-Opiate-induced diuresis) (Ureta, H. (135) 289)

**Tolerance**
Phencyclidine; Supersensitivity; Stereotyped behavior (Repeated administration) (Nabeshima, T. (135) 23)

**Transmitter release**
ω-Conotoxin; Sympathetic ganglion; Neuromuscular junction; Electric organ; $Ca^{2+}$ channel (Koyano, K. (135) 337)

**TRH**
Inositol phopshates; Anterior pituitary; Protein kinase C; Phorbol esters; $GH_3$ cells (Sortino, M. (135) 77)

**Triethyltin**
Brain phenolamines; Enzymes (Rat) (Coulon, J.F. (135) 53)

**Trimetoquinol**
Tetrahydroisoquinolines; $\beta_2/\beta_1$-Selectivity ratio; Thromboxane $A_2$ antagonism; Trimetoquinol analogues (N-substituted) (Fedyna, J.S. (135) 161)

**Trimetoquinol analogues (N-substituted)**
Trimetoquinol; Tetrahydroisoquinolines; $\beta_2/\beta_1$-Selectivity ratio; Thromboxane $A_2$ antagonism (Fedyna, J.S. (135) 161)

**Tryptophan hydroxylase**
Dopamine; 6-Hydroxydopamine; Methamphetamine; Neurotoxicity (Johnson, M. (135) 231)

**Ultrafiltration coefficient**
Glomeruli (isolated); Glomerular cross-sectional area; Glomerular filtration surface; PAF; Atrial natriuretic peptide (Rat) (Barrio, V. (135) 93)

**Use dependence**
Cellular electrophysiology; Antiarrhythmic drugs; Arrhythmogenic mechanisms; Purkinje fibers (Johnson, N. (135) 41)

**Vascular smooth muscle cells**
Atrial natriuretic peptide; Receptor down-regulation; cGMP (Hirata, Y. (135) 439)

**Vas deferens**
Adrenergic responses; Non-adrenergic responses; $\alpha_1$-Adrenoceptor potentiation; Nifedipine; Verapamil; Idazoxan (Rat) (Amobi, N.I.B. (135) 173)

**Vasopressins**
Phosphoinositides; Drug antagonism; Muscle (smooth, vascular) (Endogenous substances, Receptors) (Fox, A.W. (135) 1)

**Verapamil**
Vas deferens; Adrenergic responses; Non-adrenergic responses; $\alpha_1$-Adrenoceptor potentiation; Nifedipine; Idazoxan (Rat) (Amobi, N.I.B. (135) 173)

**WEB 2086**
PAF; PAF antagonists; Endotoxin shock (Casals-Stenzel, J. (135) 117)

**Wistar-Kyoto rats**
Norepinephrine; Caudal artery; Spontaneously hypertensive rats; Noradrenergic transmission; Hypertension (Westfall, T.C. (135) 433)

**Yawning**
$5HT_{1B}$ receptors; Penile erections; Serotonin-mimetic compounds; Serotonin receptor antagonists; Serotonin uptake inhibitors (Berendsen, H.H.G. (135) 279)

**Yohimbine**
Adrenaline; Aspirin; Clonidine; PAF-acether; Platelet (Fouque, F. (135) 211)